Rockwell Medical, Inc. (RMTI) stock
Close on Nov 17, 2026Market cap $26.64MP/E –Yield –
Earnings
Rockwell Medical's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Rockwell Medical's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 25, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026before the open | $19.10M | +20.1% | -$0.59 | -$0.07 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026before the open | $17.80M | +10.6% | -$0.34 | -$0.04 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | $17.30M | -8.5% | -$0.04 | -$0.01 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 26, 2026before the open | $18.30M | -25.9% | -$0.01 | $0.02 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025before the open | $15.90M | -43.8% | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 14, 2025before the open | $16.10M | – | -$0.05 | -$0.01 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025before the open | $18.90M | -16.7% | -$0.04 | -$0.01 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 20, 2025before the open | $24.70M | +11.8% | -$0.02 | $0.04 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024before the open | $28.30M | +18.9% | $0.05 | $0.09 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 14, 2024before the open | $22.70M | +15.2% | -$0.06 | -$0.02 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 21, 2024before the open | $22.10M | +14.5% | -$0.05 | $0.02 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023before the open | $23.80M | +27.3% | -$0.07 | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023before the open | $18.10M | -3.2% | -$0.18 | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 15, 2023before the open | $19.70M | +22.4% | -$0.10 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 30, 2023before the open | $19.30M | – | -$0.20 | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022before the open | $18.70M | +16.9% | -$0.40 | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022before the open | $18.70M | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 16, 2022after the close | $16.10M | – | -$0.84 | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 15, 2021after the close | $16.00M | – | $0.08 | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 16, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 17, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 31, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 9, 2020after the close | – | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 10, 2020after the close | – | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 11, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Rockwell Medical's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Net Sales | FY2026 | $70.00M – $75.00M | $70.00M – $75.00M | Reaffirmed | Aug 13, 2026 |
| Gross Margin | FY2026 | 18% – 22% | 18% – 22% | Reaffirmed | Aug 13, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $1.00M – $2.00M | $1.00M – $2.00M | Reaffirmed | Aug 13, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $1.00M – $2.00M | – | New | Mar 26, 2026 |
Guidance vs results
The last range Rockwell Medical gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $65.00M – $70.00M | $69.20MΣ4Q | Within range |
| Q4 FY2023 | Revenue | $21.30M – $22.30M | $22.10M | Within range |
| Q3 FY2023 | Revenue | $21.00M – $23.00M | $23.80M | Above range |
Guidance history
Every forecast Rockwell Medical put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 13, 2026 | Adjusted EBITDA | FY2026 | $1.00M – $2.00M | Reaffirmed |
| Aug 13, 2026 | Gross Margin | FY2026 | 18% – 22% | Reaffirmed |
| Aug 13, 2026 | Net Sales | FY2026 | $70.00M – $75.00M | Reaffirmed |
| May 7, 2026 | Adjusted EBITDA | FY2026 | $1.00M – $2.00M | New |
| May 7, 2026 | Gross Margin | FY2026 | 18% – 22% | New |
| May 7, 2026 | Net Sales | FY2026 | $70.00M – $75.00M | New |
| Mar 26, 2026 | Adjusted EBITDA | FY2026 | $1.00M – $2.00M | New |
| Nov 12, 2025 | Net Sales | FY2025 | $65.00M – $70.00M | New |
| Aug 14, 2025 | Adjusted EBITDA | FY2025 | -$500.00K – $500.00K | Reaffirmed |
| Aug 14, 2025 | Gross Margin | FY2025 | 16% – 18% | Reaffirmed |
| Aug 14, 2025 | Net Sales | FY2025 | $65.00M – $70.00M | Reaffirmed |
| May 12, 2025 | Adjusted EBITDA | FY2025 | -$500.00K – $500.00K | Reaffirmed |
| May 12, 2025 | Gross Margin | FY2025 | 16% – 18% | Reaffirmed |
| May 12, 2025 | Net Sales | FY2025 | $65.00M – $70.00M | Reaffirmed |
| Mar 20, 2025 | Adjusted EBITDA | FY2025 | -$500.00K – $500.00K | New |
| Mar 20, 2025 | Gross Margin | FY2025 | 16% – 18% | New |
| Mar 20, 2025 | Net Sales | FY2025 | $65.00M – $70.00M | New |
| Nov 12, 2024 | Adjusted EBITDA | FY2024 | $4.00M – $5.00M | Raised |
| Nov 12, 2024 | Gross Margin | FY2024 | 16% – 18% | New |
| Nov 12, 2024 | Gross Profit | FY2024 | $15.00M – $17.00M | New |
| Nov 12, 2024 | Net (Product) Sales | FY2024 | $98.00M – $101.00M | New |
| May 14, 2024 | Adjusted EBITDA | FY2024 | $500.00K – $1.00M | Raised |
| May 14, 2024 | Gross Margin | FY2024 | 14% – 16% | Reaffirmed |
| May 14, 2024 | Gross Profit | FY2024 | $13.00M – $15.00M | Raised |
| May 14, 2024 | Net Sales | FY2024 | $90.00M – $94.00M | Raised |
| Mar 21, 2024 | Adjusted EBITDA | FY2024 | $0 – $500.00K | New |
| Mar 21, 2024 | Gross Margin | FY2024 | 14% – 16% | New |
| Mar 21, 2024 | Gross Profit | FY2024 | $12.00M – $14.00M | New |
| Mar 21, 2024 | Net (Product) Sales | FY2024 | $84.00M – $88.00M | New |
| Jan 8, 2024 | adjusted EBITDA | Q4 FY2023 | -$900.00K – $100.00K | New |
| Jan 8, 2024 | adjusted EBITDA | FY2023 | -$5.50M – -$4.50M | New |
| Jan 8, 2024 | gross profit | Q4 FY2023 | $1.60M – $2.60M | New |
| Jan 8, 2024 | gross profit | FY2023 | $7.40M – $8.40M | Lowered |
| Jan 8, 2024 | net sales | Q4 FY2023 | $21.30M – $22.30M | New |
| Jan 8, 2024 | net sales | FY2023 | $82.80M – $83.80M | Narrowed |
| Nov 14, 2023 | gross profit | FY2023 | $8.00M – $10.00M | Reaffirmed |
| Nov 14, 2023 | net sales | FY2023 | $82.00M – $86.00M | Reaffirmed |
| Aug 14, 2023 | gross profit | FY2023 | $8.00M – $10.00M | New |
| Aug 14, 2023 | net sales | Q3 FY2023 | $21.00M – $23.00M | New |
| Aug 14, 2023 | Net Sales | FY2023 | $82.00M – $86.00M | Raised |
| May 15, 2023 | gross profit | FY2023 | $7.00M – $9.00M | Reaffirmed |
| May 15, 2023 | revenue | FY2023 | $78.00M – $82.00M | Reaffirmed |
| Mar 30, 2023 | Gross Profit | FY2023 | $7.00M – $9.00M | New |
| Mar 30, 2023 | Net Sales | FY2023 | $78.00M – $82.00M | New |
| Nov 14, 2022 | total annual revenue | FY2022 | $65.00M – $70.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Rockwell Medical filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- News
- Update
- Results
- Update
- Results
- Results
- Update
- Results
- Results
- Update
- Results
- Update
See a number that looks wrong?